ストックスクリーナーアプリを入手
39.95
4.74%
1.76
前日終値:
$38.19
開ける：
$38.14
24時間の取引高:
3.03M
Relative Volume:
0.84
時価総額：
$4.50B
収益：
-
当期純損益:
$-99.15M
株価収益率:
-42.96
EPS:
-0.93
ネットキャッシュフロー:
$-74.25M
1週間 パフォーマンス:
+17.54%
1か月 パフォーマンス:
+28.58%
6か月 パフォーマンス:
+36.43%
1年 パフォーマンス:
-31.50%
1日の値動き範囲:
$37.75
$40.09
1週間の範囲:
$31.30
$40.13
52週間の値動き範囲:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
40.01 | 4.26B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.06 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.63 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.96 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.46 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.88 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - The Globe and Mail
Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735 - Insider Monkey
Viking Therapeutics Inc. Builds Base for Possible ReboundCommunity Entry Consensus Trade Ideas Shared - beatles.ru
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts - AOL.com
Viking Therapeutics Surges 6.55% on High-Volume Momentum Ranking 373rd as Liquidity-Driven Strategy Yields 166.71% Return - AInvest
Viking Therapeutics Stock Climbs on Promising Drug Results - TipRanks
Viking Therapeutics' VK2735 maintains competitive edge despite disappointing Eli Lilly data. - AInvest
Viking Therapeutics' VK2735 Shows Promising Phase 1 Results, Justifying Buy Rating - AInvest
Viking Therapeutics Surges 11.54% to 408th in Volume Amid Eli Lilly's Setback - AInvest
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Why Viking Therapeutics Stock is Climbing - TipRanks
Promising Phase 1 Results for Viking Therapeutics’ VK2735 Justify Buy Rating - TipRanks
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - Benzinga
Eli Lilly’s obesity drug data lifts Viking Therapeutics stock By Investing.com - Investing.com Canada
Viking Therapeutics Soars 11.39% on Acquisition Hopes, Obesity Drug Progress - AInvest
Three Stocks Showing Strong Buy Signals - AInvest
Is It Time to Buy Biotech Stocks? - The Motley Fool
Unlocking Viking Therapeutics' Potential with Upcoming Clinical Data - AInvest
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial - MSN
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True? - MSN
This Biotech Stock Could Soar on Upcoming Clinical Data - AOL.com
Two Biotech Stocks with High Upside Potential: Viking Therapeutics and Recursion Pharmaceuticals - AInvest
What is the risk reward ratio of investing in Viking Therapeutics Inc. stockUnmatched market gains - Jammu Links News
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - The Globe and Mail
What institutional investors are buying Viking Therapeutics Inc. stockNavigate the market with precision tools - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - Yahoo Finance
When is Viking Therapeutics Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - Jammu Links News
What is the dividend policy of Viking Therapeutics Inc. stockExplosive earnings growth - Jammu Links News
What makes Viking Therapeutics Inc. stock price move sharplyGet professional advice for portfolio optimization - Jammu Links News
Is it the right time to buy Viking Therapeutics Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
Is Viking Therapeutics Inc. stock overvalued or undervaluedFree Stock Selection - Jammu Links News
What are analysts’ price targets for Viking Therapeutics Inc. in the next 12 monthsMarket-beating returns - Jammu Links News
Is Viking Therapeutics the Next Big Biotech Bet? - AOL.com
Viking Therapeutics: A Promising Buy with Strategic Opportunities in Obesity Treatment and Direct-to-Consumer Market - TipRanks
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - AOL.com
Viking Bets Big On Obesity And NASH With Dual-Agonist Pipeline - Finimize
Axsome Therapeutics and Viking Therapeutics: Biotech Stocks to WatchNews and Statistics - IndexBox
Wall Street Predicts Axsome Therapeutics and Viking Therapeutics Stocks to Soar 74% to 159% - AInvest
Why Viking Therapeutics Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
Sentiment Turns Positive on Viking Therapeutics Inc. — Reversal AheadMarket Entry and Exit Point Tips From Traders - metal.it
How does Viking Therapeutics Inc. compare to its industry peersDynamic investment growth - Jammu Links News
Raymond James Financial Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
Why is Viking Therapeutics Inc. stock attracting strong analyst attentionTriple returns potential - Jammu Links News
What catalysts could drive Viking Therapeutics Inc. stock higher in 2025Rapid market gains - Jammu Links News
What are the technical indicators suggesting about Viking Therapeutics Inc.Unlock steady growth with low-risk stocks - jammulinksnews.com
Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
0.77%
2.87%
大文字化:
|
ボリューム (24 時間):